Recent Advance in Drug Development of Squamous Cell Carcinoma

Title:Recent Advance in Drug Development of Squamous Cell Carcinoma

Volume: 15 Issue: 7

Author(s): Jun Lei, Bing Fu, Hang Yin, Guanxiu Tang, Shujuan Zhu, Chunli Yan and Quanyong He

Affiliation:

Keywords: Drug, epidermal growth factor receptor, esophageal, head and neck, lung, squamous cell carcinoma, target therapy, toll-like receptor.

Abstract: Squamous cell carcinoma (SCC) has a high worldwide incidence that is commonly seen as head and neck cancers, esophageal cancers, and non-small cell lung cancers. There is a poor prognosis for SCC due to potential recurrence and its metastatic tendency so the 5-year survival rate is very low. Target therapy is a novel and promising treatment strategy exhibiting great anti-tumor effects and survival benefits in SCC. This review summarizes current treatment strategies from clinical and experimental studies, including the agents targeting epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, CXCR, and the related combination therapy regimens. However, there are still many challenges we have to face. It is a burning need to improve the development and availability of drug formulations.

Cite this article as:

Lei Jun, Fu Bing, Yin Hang, Tang Guanxiu, Zhu Shujuan, Yan Chunli and He Quanyong, Recent Advance in Drug Development of Squamous Cell Carcinoma, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (7) . https://dx.doi.org/10.2174/1871520615666150113103938